1-[2-(Dimethylamino)ethoxy]-2-methylprop-2-en-1-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-(Dimethylamino)ethoxy]-2-methylprop-2-en-1-ol
• 英文别名: 1-[2-(dimethylamino)ethoxy]-2-methylprop-2-en-1-ol
• 化学式: C₈H₁₇NO₂
• 分子量: 159.23
• InChiKey: IXGOKWFBIDGHLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Calcium peroxides nanoparticles as adjuvant therapy
  申请人：UNIVERSITY OF ULSTER

  公开号：US11235000B2

  公开（公告）日：2022-02-01

  The invention provides CaO2 nanoparticles having a pH-responsive coating for use in a method of adjuvant therapy of hypoxic tumour cells or tissues. The nanoparticles find particular use in enhancing cancer therapies that depend on oxygen to exert their effect, such as photodynamic therapy (PDT), sonodynamic therapy (SDT), and radiotherapy. The invention also provides pharmaceutical compositions containing the coated CaO2 nanoparticles, together with at least one photosensitiser, sonosensitiser, or radiosensitiser and, optionally, at least one pharmaceutical carrier or excipient.

  本发明提供了具有 pH 响应涂层的 CaO2 纳米粒子，可用于缺氧肿瘤细胞或组织的辅助治疗方法。这种纳米粒子特别适用于增强依赖氧气发挥疗效的癌症疗法，如光动力疗法（PDT）、声动力疗法（SDT）和放射疗法。本发明还提供了含有涂层 纳米粒子的药物组合物，以及至少一种光敏剂、声敏剂或放射敏剂和可选的至少一种药物载体或赋形剂。
• FUNCTIONALIZED 4- AND 5-VINYL SUBSTITUTED REGIOISOMERS OF 1,2,3-TRIAZOLES VIA 1,3-DIPOLAR CYCLOADDITION AND POLYMERS THEREOF
  申请人：ISP Investments Inc.

  公开号：EP2405757B1

  公开（公告）日：2017-11-08
• CALCIUM PEROXIDES NANOPARTICLES AS ADJUVANT THERAPY
  申请人：UNIVERSITY OF ULSTER

  公开号：US20200069727A1

  公开（公告）日：2020-03-05

  The invention provides CaO 2 nanoparticles having a pH-responsive coating for use in a method of adjuvant therapy of hypoxic tumour cells or tissues. The nanoparticles find particular use in enhancing cancer therapies that depend on oxygen to exert their effect, such as photodynamic therapy (PDT), sonodynamic therapy (SDT), and radiotherapy. The invention also provides pharmaceutical compositions containing the coated CaO 2 nanoparticles, together with at least one photosensitiser, sonosensitiser, or radiosensitiser and, optionally, at least one pharmaceutical carrier or excipient.